132 related articles for article (PubMed ID: 32270727)
1. The economic burden to payers of patients with diffuse large B-cell lymphoma during the treatment period by line of therapy.
Tkacz J; Garcia J; Gitlin M; McMorrow D; Snyder S; Bonafede M; Chung KC; Maziarz RT
Leuk Lymphoma; 2020 Jul; 61(7):1601-1609. PubMed ID: 32270727
[TBL] [Abstract][Full Text] [Related]
2. Burden of Illness and Treatment Patterns in Second-line Large B-cell Lymphoma.
Snider JT; McMorrow D; Song X; Diakun D; Wade SW; Cheng P
Clin Ther; 2022 Apr; 44(4):521-538. PubMed ID: 35241295
[TBL] [Abstract][Full Text] [Related]
3. Economic burden and treatment patterns for patients with diffuse large B-cell lymphoma and follicular lymphoma in the USA.
Ren J; Asche CV; Shou Y; Galaznik A
J Comp Eff Res; 2019 Apr; 8(6):393-402. PubMed ID: 30855175
[TBL] [Abstract][Full Text] [Related]
4. Costs of relapsed diffuse large B-cell lymphoma among Medicare patients.
Huntington S; Keshishian A; McGuire M; Xie L; Baser O
Leuk Lymphoma; 2018 Dec; 59(12):2880-2887. PubMed ID: 29936866
[TBL] [Abstract][Full Text] [Related]
5. Real-world treatment patterns, survival, health resource use and costs among Medicare beneficiaries with diffuse large B-cell lymphoma.
Garg M; Puckett J; Kamal-Bahl S; Raut M; Ryland KE; Doshi JA; Huntington SF
Future Oncol; 2024 Feb; 20(6):317-328. PubMed ID: 38050764
[TBL] [Abstract][Full Text] [Related]
6. Direct Costs Associated with Relapsed Diffuse Large B-Cell Lymphoma Therapies.
Purdum A; Tieu R; Reddy SR; Broder MS
Oncologist; 2019 Sep; 24(9):1229-1236. PubMed ID: 30850561
[TBL] [Abstract][Full Text] [Related]
7. Real-World Survival, Healthcare Resource Utilization, and Costs Among U.S. Elderly Patients With Diffuse Large B-Cell Lymphoma (DLBCL) Treated With R-GemOx in the Relapsed/Refractory Setting.
Garg M; Puckett J; Kamal-Bahl S; Raut M; Ryland KE; Doshi JA; Huntington SF
Clin Lymphoma Myeloma Leuk; 2024 May; 24(5):e181-e190. PubMed ID: 38433043
[TBL] [Abstract][Full Text] [Related]
8. Overall survival, costs, and healthcare resource use by line of therapy in Medicare patients with newly diagnosed metastatic urothelial carcinoma.
Aly A; Johnson C; Yang S; Botteman MF; Rao S; Hussain A
J Med Econ; 2019 Jul; 22(7):662-670. PubMed ID: 30836812
[No Abstract] [Full Text] [Related]
9. Second-line therapy in diffuse large B-cell lymphoma (DLBCL): treatment patterns and outcomes in older patients receiving outpatient chemotherapy.
Danese MD; Griffiths RI; Gleeson ML; Dalvi T; Li J; Mikhael JR; Deeter R; Dreyling M
Leuk Lymphoma; 2017 May; 58(5):1094-1104. PubMed ID: 27659997
[TBL] [Abstract][Full Text] [Related]
10. Treatment patterns and comparative effectiveness in elderly diffuse large B-cell lymphoma patients: a surveillance, epidemiology, and end results-medicare analysis.
Hamlin PA; Satram-Hoang S; Reyes C; Hoang KQ; Guduru SR; Skettino S
Oncologist; 2014 Dec; 19(12):1249-57. PubMed ID: 25342313
[TBL] [Abstract][Full Text] [Related]
11. Burden of illness and outcomes in second-line large B-cell lymphoma treatment: real-world analysis of Medicare beneficiaries.
Kilgore KM; Mohammadi I; Wong AC; Snider JT; Cheng P; Schroeder A; Patel AR
Future Oncol; 2021 Dec; 17(35):4837-4847. PubMed ID: 34645318
[TBL] [Abstract][Full Text] [Related]
12. Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Is It a Valid Treatment Option?
Mondello P; Steiner N; Willenbacher W; Ferrero S; Ghione P; Marabese A; Pitini V; Cuzzocrea S; Mian M
Oncologist; 2016 Sep; 21(9):1107-12. PubMed ID: 27382029
[TBL] [Abstract][Full Text] [Related]
13. Economic burden of patients with diffuse large B-cell and follicular lymphoma treated in the USA.
Morrison VA; Bell JA; Hamilton L; Ogbonnaya A; Shih HC; Hennenfent K; Eaddy M; Shou Y; Galaznik A
Future Oncol; 2018 Oct; 14(25):2627-2642. PubMed ID: 29911900
[TBL] [Abstract][Full Text] [Related]
14. A nationwide analysis of the treatment patterns, survival, and medical costs in Korean patients with relapsed or refractory diffuse large B-cell lymphoma.
Cho JY; Jang SC; Kang DW; Lee EK; Koh H; Yoon DH; Park MH
Front Oncol; 2024; 14():1282323. PubMed ID: 38361777
[TBL] [Abstract][Full Text] [Related]
15. Economic Burden of Neurologic Toxicities Associated with Treatment of Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma in the United States.
Broder MS; Ma Q; Yan T; Zhang J; Chang E; Kuzan D; Eldjerou L
Am Health Drug Benefits; 2020; 13(5):192-199. PubMed ID: 33343819
[TBL] [Abstract][Full Text] [Related]
16. Comparative effectiveness and cost of adding rituximab to first-line chemotherapy for elderly patients diagnosed with diffuse large B-cell lymphoma.
Griffiths RI; Gleeson ML; Mikhael J; Dreyling MH; Danese MD
Cancer; 2012 Dec; 118(24):6079-88. PubMed ID: 22648454
[TBL] [Abstract][Full Text] [Related]
17. A salvage chemotherapy of R-P-IMVP16/CBDCA consisting of rituximab, methylprednisolone, ifosfamide, methotrexate, etoposide, and carboplatin for patients with diffuse large B cell lymphoma who had previously received R-CHOP therapy as first-line chemotherapy.
Matsumoto T; Hara T; Shibata Y; Nakamura N; Nakamura H; Ninomiya S; Kitagawa J; Kanemura N; Goto N; Kito Y; Kasahara S; Yamada T; Sawada M; Miyazaki T; Takami T; Takeuchi T; Moriwaki H; Tsurumi H
Hematol Oncol; 2017 Sep; 35(3):288-295. PubMed ID: 26999778
[TBL] [Abstract][Full Text] [Related]
18. Nationwide claims database analysis of treatment patterns, costs and survival of Japanese patients with diffuse large B-cell lymphoma.
Tsutsué S; Tobinai K; Yi J; Crawford B
PLoS One; 2020; 15(8):e0237509. PubMed ID: 32810157
[TBL] [Abstract][Full Text] [Related]
19. Characterizing Autoimmune Disease-associated Diffuse Large B-cell Lymphoma in a SEER-Medicare Cohort.
Koff JL; Rai A; Flowers CR
Clin Lymphoma Myeloma Leuk; 2018 Feb; 18(2):e115-e121. PubMed ID: 29273217
[TBL] [Abstract][Full Text] [Related]
20. Inpatient treatment of relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL): A health economic perspective.
Moertl B; Dreyling M; Schmidt C; Hoster E; Schoel W; Bergwelt-Baildon MV; Berger K
Clin Lymphoma Myeloma Leuk; 2022 Jul; 22(7):474-482. PubMed ID: 35033478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
